Pioglitazone After Ischemic Stroke or TIA - IRIS Study Critically Examined

Print
Moderator: 
Margaret Miklich, Pharm.D.
Panelists: 
Curtis Triplitt, Pharm.D., CDE
Joel Marrs, Pharm.D., BCPS AQ Cardiology, BCACP
Reviewed By: 
Amanda Schartel, Pharm.D, BCACP
Stuart Haines, Pharm.D., BCPS, BCACP
Citation: 
Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Eng J Med 2016; 374: 1321-31.

Patients who've had an ischemic stroke or transient ischemic attack (TIA) are at very high risk for recurrent vascular events. The current standard of care is to address cardiovascular risk factors. The Insulin Resistance Intervention after Stroke (IRIS) trial examined the benefits and risks of pioglitazone use after a recent ischemic stroke or TIA. In this video the methodology and results of the IRIS study are presented and our panelists discuss the strengths, weakness, and clinical implications of the study.